Recent Updates on the Significance of KRAS Mutations in Colorectal Cancer Biology

Recent Updates on the Significance of KRAS Mutations in Colorectal Cancer Biology

The most commonly mutated isoform of RAS among all cancer subtypes is KRAS. In this review, we focus on the special role of KRAS mutations in colorectal cancer (CRC), aiming to collect recent data on KRAS-driven enhanced cell signalling, in vitro and in vivo research models, and CRC development-rela...

Full description

Bibliographic Details
Main Authors:	Loretta László, Anita Kurilla, Tamás Takács, Gyöngyi Kudlik, Kitti Koprivanacz, László Buday, Virag Vas
Format:	Article
Language:	English
Published:	MDPI AG 2021-03-01
Series:	Cells
Subjects:	KRAS colorectal cancer RAS signalling cancer stem cells RAS-driven metastasis CRC with age
Online Access:	https://www.mdpi.com/2073-4409/10/3/667

Similar Items

Prevalence of RAS and BRAF mutations in metastatic colorectal cancer patients by tumor sidedness: A systematic review and meta‐analysis
by: Lauren C. Bylsma, et al.
Published: (2020-02-01)

KRAS and BRAF mutations in Iranian colorectal cancer patients: A systematic review and meta-analysis
by: Abolfazl Yari, et al.
Published: (2020-06-01)

Common and mutation specific phenotypes of KRAS and BRAF mutations in colorectal cancer cells revealed by integrative -omics analysis
by: Snehangshu Kundu, et al.
Published: (2021-07-01)

The Prevalence of BRAF, PIK3CA, and RAS Mutations in Indian Patients with Colorectal Cancer
by: Omshree Shetty, et al.
Published: (2022-07-01)

KRAS-associated microRNAs in colorectal cancer
by: Hamizah Ibrahim, et al.
Published: (2020-07-01)

The current understanding of KRAS protein structure and dynamics
by: Tatu Pantsar
Published: (2020-01-01)

Differential landscape of immune evasion in oncogenic RAS-driven primary and metastatic colorectal cancers
by: Emil Lou, et al.
Published: (2024-03-01)

PPARγ-activation increases intestinal M1 macrophages and mitigates formation of serrated adenomas in mutant KRAS mice
by: Tobias Gutting, et al.
Published: (2018-05-01)

The Yeast Saccharomyces cerevisiae as a Model for Understanding RAS Proteins and their Role in Human Tumorigenesis
by: Giulia Cazzanelli, et al.
Published: (2018-02-01)

OPTIMIZATION OF METASTATIC COLORECTAL CANCER TREATMENT WITH RAS MUTATIONS
by: L. V. Bolotina
Published: (2015-02-01)

The quaternary assembly of KRas4B with Raf-1 at the membrane
by: Hyunbum Jang, et al.
Published: (2020-01-01)

Novel Roles of SH2 and SH3 Domains in Lipid Binding
by: Szabolcs Sipeki, et al.
Published: (2021-05-01)

Panitumumab use in metastatic colorectal cancer and patterns of RAS testing: results from a Europe-wide physician survey and medical records review
by: J. Han van Krieken, et al.
Published: (2017-11-01)

The relationships of OSBPL3 expression with KI-67 expression and KRAS mutations in CRC: implications for diagnosis and prognosis
by: Min Zhang, et al.
Published: (2022-12-01)

Precision Therapy of Metastatic Colorectal Cancer with RAS Mutation
by: ZOU Jiayun, et al.
Published: (2021-08-01)

Coexistence of KRAS and BRAF Mutations in Colorectal Cancer: A case report supporting the concept of tumoral heterogeneity
by: Pegah Larki, et al.
Published: (2017-05-01)

K-ras Mutation in Colorectal Cancer, A Report from Southern Iran
by: Navid Omidifar, et al.
Published: (2015-09-01)

Concurrent mutation in exons 1 and 2 of the K-ras oncogene in colorectal cancer
by: Fiorella Guadagni, et al.
Published: (2012-01-01)

Analysis of the role of RAS Family Mutations in Metastatic Colorectal Cancer (mCRC): Current Treatment Practice
by: Saridaki Zenia, et al.
Published: (2014-12-01)

Genomic landscape and survival analysis of ctDNA “neo-RAS wild-type” patients with originally RAS mutant metastatic colorectal cancer
by: Chiara Nicolazzo, et al.
Published: (2023-03-01)

Clinico-pathological associations and concomitant mutations of the RAS/RAF pathway in metastatic colorectal cancer
by: Edoardo Isnaldi, et al.
Published: (2019-04-01)

Targeting RAS – will GPR31 deliver us a new path forward?
by: Nicole Fehrenbacher, et al.
Published: (2017-11-01)

The five-year KRAS, NRAS and BRAF analysis results and treatment patterns in daily clinical practice in Slovenia in 1st line treatment of metastatic colorectal (mCRC) patients with RAS wild-type tumour (wtRAS) – a real- life data report 2013–2018
by: Mesti Tanja, et al.
Published: (2023-03-01)

Subcellular compartmentalization of docking protein-1 contributes to progression in colorectal cancer
by: Teresa Friedrich, et al.
Published: (2016-06-01)

Natural Products Attenuating Biosynthesis, Processing, and Activity of Ras Oncoproteins: State of the Art and Future Perspectives
by: Renata Tisi, et al.
Published: (2020-11-01)

Parvimonas micra activates the Ras/ERK/c-Fos pathway by upregulating miR-218-5p to promote colorectal cancer progression
by: Yuxiao Chang, et al.
Published: (2023-01-01)

Monitoring ctDNA RAS Mutational Status in Metastatic Colorectal Cancer: A Trial Protocol of RAS-trace and RAS-trace-2 Studies
by: Kozo Kataoka, et al.
Published: (2024-04-01)

Targeting KRAS: from metabolic regulation to cancer treatment
by: Yanyan Shi, et al.
Published: (2025-01-01)

Predicting prognosis in colorectal cancer patients with curative resection using albumin, lymphocyte count and RAS mutations
by: Toshiya Miyata, et al.
Published: (2024-06-01)

The prevalence of KRAS and BRAF mutation in colorectal cancer patients in Bali
by: Ayu Dewi Ni Nyoman, et al.
Published: (2022-03-01)

A Bioinformatic Analysis Predicts That Cannabidiol Could Function as a Potential Inhibitor of the MAPK Pathway in Colorectal Cancer
by: Julianne du Plessis, et al.
Published: (2024-08-01)

Exploring Better Strategies for RAS Mutation-Associated EGFR-Targeted Resistance in Colorectal Cancer: From the Perspective of Cancer Community Ecology
by: Xiaojie Wang, et al.
Published: (2021-10-01)

Acquisition of Anoikis Resistance Promotes the Emergence of Oncogenic K-ras Mutations in Colorectal Cancer Cells and Stimulates Their Tumorigenicity In Vivo
by: Mathieu Derouet, et al.
Published: (2007-07-01)

Molecular-genetic mechanisms of the signal cascade RAS-RAF-MEK-ERK associated with the development of the tumor process and the purpose of targeted drugs for colorectal cancer
by: A. N. Toropovsky, et al.
Published: (2021-08-01)

Probable autoimmune lymphoproliferative syndrome with monogenic lupus due to KRAS mutation - A rare encounter
by: Amiya Nayak, et al.
Published: (2024-02-01)

Anti-colorectal cancer effects of anti-p21Ras scFv delivered by the recombinant adenovirus KGHV500 and cytokine-induced killer cells
by: Fang-Rui Liu, et al.
Published: (2018-11-01)

Correlation between KRAS, NRAS and BRAF mutations and tumor localizations in patients with primary and metastatic colorectal cancer
by: Aleksandra Bożyk, et al.
Published: (2021-03-01)

The clinicopathologic features of colorectal adenocarcinoma with respect to mismatch repair genes and KRAS status: a retrospective study
by: Z. Abbas Abadi, et al.
Published: (2021-01-01)

Editorial: Recent advances in liquid biopsy in colorectal cancer
by: Claudia Cardone, et al.
Published: (2022-12-01)

The role of KRAS and NRAS mutation detection in determining the therapy strategy for colorectal cancer
by: A. N. Toropovskiy, et al.
Published: (2022-11-01)